Verification evidence is still being completed.
PDF / print export
Kuopio Center for Gene and Cell Therapy
Kuopio, Finland
- Verified lead
- Tuija Kekarainen
- Lead status
- STATUS: VERIFIED APRIL 2026
- Leadership verification
- Scientific Director and Cell Therapy Unit Director
- 2026 technical specialization
- GMP Viral-Vector Manufacturing, AAV, Adenovirus, Lentivirus, and ATMP CDMO Services
- Review cycle
- 24 April 2026
- Full address
- Sadekuja 5, 70210 Kuopio, Finland (Finport, Savilahti campus)
- Site coordinates
- Verification evidence is still being completed.
- Editorial review
- Memel Biotech editorial review
- Official leadership source
- Health Europa profile identifying Tuija Kekarainen as Scientific Director of the Kuopio Center for Gene and Cell Therapy.
- Editorial note
- Kuopio ATMP CDMO with Fimea GMP manufacturer's authorization, viral-vector manufacturing across AAV, adenovirus, and lentivirus, and a 2020 Ferring Ventures ownership record.
GMP Viral-Vector Manufacturing, AAV, Adenovirus, Lentivirus, and ATMP CDMO Services
Fimea GMP manufacturer's authorization, ATMP CDMO service scope, Savilahti campus infrastructure
Kuopio ATMP CDMO with Fimea GMP manufacturer's authorization, viral-vector manufacturing across AAV, adenovirus, and lentivirus, and a 2020 Ferring Ventures ownership record.
Review coverage
Leadership
Facility
Certifications
Capabilities
Partners
Sources
Quality
Editorial verificationMemel Biotech directory review sign-off
Report generated02 Jun 2026, 01:40
Kuopio ATMP CDMO with Fimea GMP manufacturer's authorization, viral-vector manufacturing across AAV, adenovirus, and lentivirus, and a 2020 Ferring Ventures ownership record.
- Lead
- Tuija Kekarainen (verified ↗)
- Address
- Sadekuja 5, 70210 Kuopio, Finland (Finport, Savilahti campus) (source ↗)
- Compliance
- Fimea GMP manufacturer's authorization
- Last reviewed
- 24 Apr 2026 (1mo ago)
- Scale
- GMP viral-vector manufacturing
- Capabilities
- AAV, Adenovirus, and Lentivirus Manufacturing · Process Development for Gene and Cell Therapy · Fill-Finish for ATMPs
- Founded
- 2010
- Headcount
- 51-200
Clinical profileSTATUS: VERIFIED APRIL 2026
Tuija Kekarainen
Scientific Director and Cell Therapy Unit Director
Full addressSadekuja 5, 70210 Kuopio, Finland (Finport, Savilahti campus)
Site coordinatesVerification evidence is still being completed.
Review cycle24 April 2026
Physical site source
KCT contact page listing the Sadekuja 5 address on the Savilahti campus.
Open sourceGMP viral-vector manufacturing
Kuopio, Finland. GMP Viral-Vector Manufacturing, AAV, Adenovirus, Lentivirus, and ATMP CDMO Services. Review completed on 24 Apr 2026.
Fimea for GMP ATMP oversight
Fimea GMP manufacturer's authorization, ATMP CDMO service scope, Savilahti campus infrastructure
GMP Viral-Vector Manufacturing, AAV, Adenovirus, Lentivirus, and ATMP CDMO Services
Kuopio ATMP CDMO with Fimea GMP manufacturer's authorization, viral-vector manufacturing across AAV, adenovirus, and lentivirus, and a 2020 Ferring Ventures ownership record.
Editorial note
KCT anchors Finnish ATMP manufacturing with documented Fimea manufacturer's authorization, a named scientific director, and a dual cell-therapy and gene-therapy service model operating from the Savilahti campus.
FULL TRUST REVIEW COMPLETE
Shown only when all seven trust checks are fully mapped in the directory.
Current review cycleApril 2026
Capabilities
Core capabilities
Primary declared technical activities and areas of operating focus.
AAV, Adenovirus, and Lentivirus Manufacturing
Process Development for Gene and Cell Therapy
Fill-Finish for ATMPs
Verification source dossier
Verification source dossier
Official source set used to support leadership, physical-site, certification, and watch-note evidence.
Infrastructure
Declared infrastructure
Viral-vector production suites
Cell-therapy process development
Fill-finish for ATMPs
Regulatory posture
Quality system coverage
GMP / GLP / ISO-13485 / FDA-Inspected are global quality-system standards. "Verified active" means the directory confirmed the certification is current; "Review in progress" means the cert status is currently being re-verified.
- GMP
- VERIFIED ACTIVE 2026
- GLP
- REVIEW IN PROGRESS 2026
- ISO-13485
- REVIEW IN PROGRESS 2026
- FDA-Inspected
- REVIEW IN PROGRESS 2026
Verification history
Verification history
24 Apr 2026: Executive identity confirmed via official management disclosure.
24 Apr 2026: Full trust review completed.
FAQ
Frequently asked questions
- Where is Kuopio Center for Gene and Cell Therapy located?
- Kuopio Center for Gene and Cell Therapy operates from Sadekuja 5, 70210 Kuopio, Finland (Finport, Savilahti campus), Kuopio, Finland.
- Who runs Kuopio Center for Gene and Cell Therapy?
- Kuopio Center for Gene and Cell Therapy is led by Tuija Kekarainen, Scientific Director and Cell Therapy Unit Director. Verified 24 Apr 2026.
- What certifications does Kuopio Center for Gene and Cell Therapy hold?
- Kuopio Center for Gene and Cell Therapy is documented under Fimea GMP manufacturer's authorization.
- What does Kuopio Center for Gene and Cell Therapy do?
- Kuopio ATMP CDMO with Fimea GMP manufacturer's authorization, viral-vector manufacturing across AAV, adenovirus, and lentivirus, and a 2020 Ferring Ventures ownership record. Core capabilities: AAV, Adenovirus, and Lentivirus Manufacturing, Process Development for Gene and Cell Therapy, Fill-Finish for ATMPs.
Editorial context
Related technical briefs
Briefs that name Kuopio as a covered market or city.